WOBURN, Mass.--(BUSINESS WIRE)--Cambria Biosciences, a privately held biopharmaceutical company, today announced that it has co-authored an article with partner Novartis Animal Health Inc. which was published in the March 13 edition of Nature. The study describes Novartis’ discovery of a new anthelmintic compound effective against parasitic nematode strains resistant to currently available treatments. Its unique mode of action was elucidated by Cambria’s chemical genetics platform, which identified a nematode-specific protein whose biological function had not been previously studied. This successful work also led to a development milestone payment from Novartis to Cambria as part of an existing collaboration between the two companies.
